Go to Page # Page of 11

Influenza Therapeutic Developments By Kimberly Armstrong

 Kimberly Armstrong
Description: Kimberly Armstrong a branch chief explaining the Influenza Therapeutics. Influenza Antivirals as of September 2018 and comparing it with a current portfolio focused on direct-acting antivirals. Studies on the patients less emphasis.
Views: 3605
Domain: Medical
Category: Biology
Influenza Therapeutics
Kimberly Armstrong, PhD, MT(ASCP)
Branch Chief (Acting), Therapeutics
October 29, 2018
October 29-30, 2018 | Grand Hyatt • Washington, D.C.

Influenza Antivirals as of September 2018

M2 blockers




Stiver 2003 CMAJ 168:49

Saving Lives. Protecting Americans.


Current ... See more

Recent Presentations

19 April, 2019

FDA Approach to the Opioids Crisis

Opioid Crisis is not one crisis, but multiple challenges to prescribers, patients & healthcare system. FDA is working in a prioritized way in multiple areas to confront opioid over

18 April, 2019
Ralph F. Hall
17 April, 2019